Plain balloon angioplasty with or without bare-metal stenting versus drug-coated balloon angioplasty with or without bare-metal stenting versus primary drug-eluting stenting in patients requiring femoropopliteal, with or without infrapopliteal, endovascular revascularization for chronic limb-threatening ischaemia: BASIL-3 within-trial health economic analysis
British Journal of Surgery · 2026
DOI: 10.1093/bjs/znaf274 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift British Journal of Surgery, 2026. Verfasst von Mishal Javed und 10 weiteren Autor:innen. Beteiligte Einrichtung: Health Economics Unit, Department of Applied Health Sciences, University of Birmingham, Birmingham, UK. Hauptthemen laut MEDLINE: Angioplasty, Balloon, Chronic Limb-Threatening Ischemia, Drug-Eluting Stents, Femoral Artery. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: UK National Institute for Health and Care Research (NIHR) Health Technology Assessment (HTA) Programme.
Abstract (Originalsprache)
Background
The BASIL-3 trial demonstrated that patients with chronic limb-threatening ischaemia secondary to femoropopliteal disease who were randomized to plain balloon angioplasty (PBA) ± bare-metal stenting (BMS), drug-coated balloon angioplasty (DCBA) ± BMS, or drug-eluting stenting (DES) had similar clinical outcomes. Herein, the in-trial health economic analysis is presented.
Methods
Cost-utility analysis (CUA) and cost-effectiveness analysis (CEA) were conducted from the perspective of the UK National Health Service (NHS) and Personal Social Services Research Unit. Patient-level resource use and health outcome data were collected from the BASIL-3 trial during 2–7 years of follow-up and were utilized to estimate incremental cost-effectiveness ratios expressed as a cost per amputation-free life-year and per quality-adjusted life-year (QALY). EQ-5D-5L was used to generate participant QALYs at baseline and during follow-up.
Results
In the CUA, DCBA was associated with slightly lower NHS costs (−£250.71 (95% c.i. −£4630.34 to £3652.10)), but slightly lower QALY gains (−0.007 (95% c.i. −0.116 to 0.097) QALYs) when compared with PBA. When compared with PBA, DES was less costly (−£724.52 (95% c.i. −£4975.04 to £2631.57)) and resulted in an additional 0.048 (95% c.i. −0.060 to 0.148) QALYs.
Conclusion
In BASIL-3, the probability of DCBA and of DES being cost-effective at £20 000 per QALY was 52% and 76% respectively. At a higher willingness-to-pay threshold (£30 000 per QALY) DES may be cost-effective and further research is required to explore the economic case.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Health Economics Unit, Department of Applied Health Sciences, University of Birmingham, Birmingham, UK.
- Birmingham Clinical Trial Unit, Department of Applied Health Sciences, University of Birmingham, Birmingham, UK.
- Department of Vascular Surgery, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
- Department of Applied Health Sciences, University of Birmingham, Birmingham, UK.
- Department of Vascular Surgery, University Hospital of Wales, Cardiff, UK.
- Department of Vascular Surgery, University of Birmingham, Birmingham, UK.
ORCID-Profile: Mishal Javed, Jesse Kigozi, Catherine A Moakes, Gareth R Bate, Jack A Hall, Jon J Deeks, Lisa Kelly, Lewis Meecham, Andrew W Bradbury, Matthew A Popplewell
Förderung
- UK National Institute for Health and Care Research (NIHR) Health Technology Assessment (HTA) Programme
Zitieren
APA
Javed, M., Kigozi, J., Moakes, C. A., Bate, G. R., Hall, J. A., Deeks, J. J., Kelly, L., Meecham, L., Bradbury, A. W., Popplewell, M. A., & BASIL-3 Investigators (2026). Plain balloon angioplasty with or without bare-metal stenting versus drug-coated balloon angioplasty with or without bare-metal stenting versus primary drug-eluting stenting in patients requiring femoropopliteal, with or without infrapopliteal, endovascular revascularization for chronic limb-threatening ischaemia: BASIL-3 within-trial health economic analysis. British Journal of Surgery. https://doi.org/10.1093/bjs/znaf274
Vancouver
Javed M, Kigozi J, Moakes CA, Bate GR, Hall JA, Deeks JJ, et al. Plain balloon angioplasty with or without bare-metal stenting versus drug-coated balloon angioplasty with or without bare-metal stenting versus primary drug-eluting stenting in patients requiring femoropopliteal, with or without infrapopliteal, endovascular revascularization for chronic limb-threatening ischaemia: BASIL-3 within-trial health economic analysis. British Journal of Surgery. 2026. doi:10.1093/bjs/znaf274
BibTeX
@article{Javed2026,
author = {Javed, Mishal and Kigozi, Jesse and Moakes, Catherine A and Bate, Gareth R and Hall, Jack A and Deeks, Jon J and Kelly, Lisa and Meecham, Lewis and Bradbury, Andrew W and Popplewell, Matthew A and BASIL-3 Investigators, BASIL-3 Investigators},
title = {Plain balloon angioplasty with or without bare-metal stenting versus drug-coated balloon angioplasty with or without bare-metal stenting versus primary drug-eluting stenting in patients requiring femoropopliteal, with or without infrapopliteal, endovascular revascularization for chronic limb-threatening ischaemia: BASIL-3 within-trial health economic analysis},
journal = {British Journal of Surgery},
year = {2026},
doi = {10.1093/bjs/znaf274}
}
EUVIMED